nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C19—Sorafenib—liver cancer	0.0785	0.383	CbGbCtD
Sitaxentan—CYP2C9—Sorafenib—liver cancer	0.0653	0.319	CbGbCtD
Sitaxentan—CYP3A4—Sorafenib—liver cancer	0.038	0.185	CbGbCtD
Sitaxentan—CYP3A4—Doxorubicin—liver cancer	0.023	0.112	CbGbCtD
Sitaxentan—Infection—Sorafenib—liver cancer	0.00103	0.00207	CcSEcCtD
Sitaxentan—Skin exfoliation—Epirubicin—liver cancer	0.00103	0.00206	CcSEcCtD
Sitaxentan—Candida infection—Epirubicin—liver cancer	0.00103	0.00206	CcSEcCtD
Sitaxentan—Inflammation—Doxorubicin—liver cancer	0.00103	0.00206	CcSEcCtD
Sitaxentan—Fluid retention—Epirubicin—liver cancer	0.00102	0.00205	CcSEcCtD
Sitaxentan—Nervous system disorder—Sorafenib—liver cancer	0.00102	0.00205	CcSEcCtD
Sitaxentan—Thrombocytopenia—Sorafenib—liver cancer	0.00102	0.00204	CcSEcCtD
Sitaxentan—Vaginal infection—Epirubicin—liver cancer	0.00102	0.00204	CcSEcCtD
Sitaxentan—Blood uric acid increased—Doxorubicin—liver cancer	0.00101	0.00204	CcSEcCtD
Sitaxentan—Skin disorder—Sorafenib—liver cancer	0.00101	0.00203	CcSEcCtD
Sitaxentan—Musculoskeletal pain—Doxorubicin—liver cancer	0.00101	0.00202	CcSEcCtD
Sitaxentan—Ventricular tachycardia—Doxorubicin—liver cancer	0.000996	0.002	CcSEcCtD
Sitaxentan—Hiccups—Doxorubicin—liver cancer	0.000996	0.002	CcSEcCtD
Sitaxentan—Pulmonary embolism—Doxorubicin—liver cancer	0.000996	0.002	CcSEcCtD
Sitaxentan—Dry eye—Epirubicin—liver cancer	0.000994	0.002	CcSEcCtD
Sitaxentan—Anorexia—Sorafenib—liver cancer	0.00099	0.00199	CcSEcCtD
Sitaxentan—Dermatitis contact—Doxorubicin—liver cancer	0.000984	0.00198	CcSEcCtD
Sitaxentan—Eructation—Doxorubicin—liver cancer	0.000978	0.00197	CcSEcCtD
Sitaxentan—Hyperkalaemia—Doxorubicin—liver cancer	0.000978	0.00197	CcSEcCtD
Sitaxentan—Neoplasm—Epirubicin—liver cancer	0.000973	0.00195	CcSEcCtD
Sitaxentan—Colitis—Doxorubicin—liver cancer	0.000956	0.00192	CcSEcCtD
Sitaxentan—Skin exfoliation—Doxorubicin—liver cancer	0.00095	0.00191	CcSEcCtD
Sitaxentan—Candida infection—Doxorubicin—liver cancer	0.00095	0.00191	CcSEcCtD
Sitaxentan—Fluid retention—Doxorubicin—liver cancer	0.000945	0.0019	CcSEcCtD
Sitaxentan—Vaginal infection—Doxorubicin—liver cancer	0.00094	0.00189	CcSEcCtD
Sitaxentan—Mental disability—Epirubicin—liver cancer	0.000934	0.00188	CcSEcCtD
Sitaxentan—Dry eye—Doxorubicin—liver cancer	0.000919	0.00185	CcSEcCtD
Sitaxentan—Dyspepsia—Sorafenib—liver cancer	0.000914	0.00184	CcSEcCtD
Sitaxentan—Decreased appetite—Sorafenib—liver cancer	0.000903	0.00181	CcSEcCtD
Sitaxentan—Neoplasm—Doxorubicin—liver cancer	0.0009	0.00181	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Sorafenib—liver cancer	0.000897	0.0018	CcSEcCtD
Sitaxentan—Fatigue—Sorafenib—liver cancer	0.000895	0.0018	CcSEcCtD
Sitaxentan—Pain—Sorafenib—liver cancer	0.000888	0.00178	CcSEcCtD
Sitaxentan—Constipation—Sorafenib—liver cancer	0.000888	0.00178	CcSEcCtD
Sitaxentan—Hepatic failure—Epirubicin—liver cancer	0.000869	0.00175	CcSEcCtD
Sitaxentan—Mental disability—Doxorubicin—liver cancer	0.000864	0.00174	CcSEcCtD
Sitaxentan—Cardiac failure congestive—Epirubicin—liver cancer	0.000861	0.00173	CcSEcCtD
Sitaxentan—Increased appetite—Epirubicin—liver cancer	0.000831	0.00167	CcSEcCtD
Sitaxentan—Menopausal symptoms—Epirubicin—liver cancer	0.000828	0.00166	CcSEcCtD
Sitaxentan—Urticaria—Sorafenib—liver cancer	0.000825	0.00166	CcSEcCtD
Sitaxentan—Body temperature increased—Sorafenib—liver cancer	0.000821	0.00165	CcSEcCtD
Sitaxentan—Renal impairment—Epirubicin—liver cancer	0.000821	0.00165	CcSEcCtD
Sitaxentan—Hepatic failure—Doxorubicin—liver cancer	0.000804	0.00162	CcSEcCtD
Sitaxentan—Hypoglycaemia—Epirubicin—liver cancer	0.0008	0.00161	CcSEcCtD
Sitaxentan—Cardiac failure—Epirubicin—liver cancer	0.0008	0.00161	CcSEcCtD
Sitaxentan—Cardiac failure congestive—Doxorubicin—liver cancer	0.000797	0.0016	CcSEcCtD
Sitaxentan—Osteoarthritis—Epirubicin—liver cancer	0.000781	0.00157	CcSEcCtD
Sitaxentan—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000781	0.00157	CcSEcCtD
Sitaxentan—Increased appetite—Doxorubicin—liver cancer	0.000769	0.00155	CcSEcCtD
Sitaxentan—Migraine—Epirubicin—liver cancer	0.000769	0.00154	CcSEcCtD
Sitaxentan—Menopausal symptoms—Doxorubicin—liver cancer	0.000766	0.00154	CcSEcCtD
Sitaxentan—Hypersensitivity—Sorafenib—liver cancer	0.000765	0.00154	CcSEcCtD
Sitaxentan—Renal impairment—Doxorubicin—liver cancer	0.000759	0.00153	CcSEcCtD
Sitaxentan—Asthenia—Sorafenib—liver cancer	0.000745	0.0015	CcSEcCtD
Sitaxentan—Hypoglycaemia—Doxorubicin—liver cancer	0.00074	0.00149	CcSEcCtD
Sitaxentan—Cardiac failure—Doxorubicin—liver cancer	0.00074	0.00149	CcSEcCtD
Sitaxentan—Ataxia—Epirubicin—liver cancer	0.000734	0.00148	CcSEcCtD
Sitaxentan—Blood creatinine increased—Epirubicin—liver cancer	0.000732	0.00147	CcSEcCtD
Sitaxentan—Dehydration—Epirubicin—liver cancer	0.000726	0.00146	CcSEcCtD
Sitaxentan—Osteoarthritis—Doxorubicin—liver cancer	0.000723	0.00145	CcSEcCtD
Sitaxentan—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000723	0.00145	CcSEcCtD
Sitaxentan—Liver function test abnormal—Epirubicin—liver cancer	0.000721	0.00145	CcSEcCtD
Sitaxentan—Dry skin—Epirubicin—liver cancer	0.000716	0.00144	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Epirubicin—liver cancer	0.000713	0.00143	CcSEcCtD
Sitaxentan—Abdominal pain upper—Epirubicin—liver cancer	0.000713	0.00143	CcSEcCtD
Sitaxentan—Migraine—Doxorubicin—liver cancer	0.000711	0.00143	CcSEcCtD
Sitaxentan—Diarrhoea—Sorafenib—liver cancer	0.000711	0.00143	CcSEcCtD
Sitaxentan—Breast disorder—Epirubicin—liver cancer	0.000706	0.00142	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000703	0.00141	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000689	0.00138	CcSEcCtD
Sitaxentan—Muscular weakness—Epirubicin—liver cancer	0.000689	0.00138	CcSEcCtD
Sitaxentan—Dizziness—Sorafenib—liver cancer	0.000687	0.00138	CcSEcCtD
Sitaxentan—Ataxia—Doxorubicin—liver cancer	0.00068	0.00137	CcSEcCtD
Sitaxentan—Blood creatinine increased—Doxorubicin—liver cancer	0.000677	0.00136	CcSEcCtD
Sitaxentan—Asthma—Epirubicin—liver cancer	0.000675	0.00136	CcSEcCtD
Sitaxentan—Dehydration—Doxorubicin—liver cancer	0.000672	0.00135	CcSEcCtD
Sitaxentan—Eosinophilia—Epirubicin—liver cancer	0.000668	0.00134	CcSEcCtD
Sitaxentan—Liver function test abnormal—Doxorubicin—liver cancer	0.000667	0.00134	CcSEcCtD
Sitaxentan—Dry skin—Doxorubicin—liver cancer	0.000662	0.00133	CcSEcCtD
Sitaxentan—Vomiting—Sorafenib—liver cancer	0.00066	0.00133	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Doxorubicin—liver cancer	0.00066	0.00133	CcSEcCtD
Sitaxentan—Abdominal pain upper—Doxorubicin—liver cancer	0.00066	0.00133	CcSEcCtD
Sitaxentan—Angina pectoris—Epirubicin—liver cancer	0.000658	0.00132	CcSEcCtD
Sitaxentan—Rash—Sorafenib—liver cancer	0.000655	0.00132	CcSEcCtD
Sitaxentan—Dermatitis—Sorafenib—liver cancer	0.000654	0.00131	CcSEcCtD
Sitaxentan—Breast disorder—Doxorubicin—liver cancer	0.000653	0.00131	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000651	0.00131	CcSEcCtD
Sitaxentan—Headache—Sorafenib—liver cancer	0.000651	0.00131	CcSEcCtD
Sitaxentan—Bronchitis—Epirubicin—liver cancer	0.000649	0.0013	CcSEcCtD
Sitaxentan—Pancytopenia—Epirubicin—liver cancer	0.000641	0.00129	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000637	0.00128	CcSEcCtD
Sitaxentan—Muscular weakness—Doxorubicin—liver cancer	0.000637	0.00128	CcSEcCtD
Sitaxentan—Dysuria—Epirubicin—liver cancer	0.000631	0.00127	CcSEcCtD
Sitaxentan—Asthma—Doxorubicin—liver cancer	0.000625	0.00126	CcSEcCtD
Sitaxentan—Pollakiuria—Epirubicin—liver cancer	0.000624	0.00125	CcSEcCtD
Sitaxentan—Eosinophilia—Doxorubicin—liver cancer	0.000618	0.00124	CcSEcCtD
Sitaxentan—Nausea—Sorafenib—liver cancer	0.000617	0.00124	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Epirubicin—liver cancer	0.000616	0.00124	CcSEcCtD
Sitaxentan—Weight decreased—Epirubicin—liver cancer	0.000611	0.00123	CcSEcCtD
Sitaxentan—Hyperglycaemia—Epirubicin—liver cancer	0.000609	0.00122	CcSEcCtD
Sitaxentan—Angina pectoris—Doxorubicin—liver cancer	0.000608	0.00122	CcSEcCtD
Sitaxentan—Infestation—Epirubicin—liver cancer	0.000602	0.00121	CcSEcCtD
Sitaxentan—Infestation NOS—Epirubicin—liver cancer	0.000602	0.00121	CcSEcCtD
Sitaxentan—Bronchitis—Doxorubicin—liver cancer	0.000601	0.00121	CcSEcCtD
Sitaxentan—Pancytopenia—Doxorubicin—liver cancer	0.000593	0.00119	CcSEcCtD
Sitaxentan—Renal failure—Epirubicin—liver cancer	0.000592	0.00119	CcSEcCtD
Sitaxentan—Stomatitis—Epirubicin—liver cancer	0.000587	0.00118	CcSEcCtD
Sitaxentan—Jaundice—Epirubicin—liver cancer	0.000587	0.00118	CcSEcCtD
Sitaxentan—Conjunctivitis—Epirubicin—liver cancer	0.000585	0.00118	CcSEcCtD
Sitaxentan—Dysuria—Doxorubicin—liver cancer	0.000584	0.00117	CcSEcCtD
Sitaxentan—Pollakiuria—Doxorubicin—liver cancer	0.000577	0.00116	CcSEcCtD
Sitaxentan—Haematuria—Epirubicin—liver cancer	0.000574	0.00115	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Doxorubicin—liver cancer	0.00057	0.00115	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Epirubicin—liver cancer	0.000569	0.00114	CcSEcCtD
Sitaxentan—Epistaxis—Epirubicin—liver cancer	0.000568	0.00114	CcSEcCtD
Sitaxentan—Weight decreased—Doxorubicin—liver cancer	0.000565	0.00114	CcSEcCtD
Sitaxentan—Sinusitis—Epirubicin—liver cancer	0.000565	0.00113	CcSEcCtD
Sitaxentan—Hyperglycaemia—Doxorubicin—liver cancer	0.000563	0.00113	CcSEcCtD
Sitaxentan—Infestation—Doxorubicin—liver cancer	0.000557	0.00112	CcSEcCtD
Sitaxentan—Infestation NOS—Doxorubicin—liver cancer	0.000557	0.00112	CcSEcCtD
Sitaxentan—Bradycardia—Epirubicin—liver cancer	0.00055	0.00111	CcSEcCtD
Sitaxentan—Renal failure—Doxorubicin—liver cancer	0.000547	0.0011	CcSEcCtD
Sitaxentan—Haemoglobin—Epirubicin—liver cancer	0.000543	0.00109	CcSEcCtD
Sitaxentan—Stomatitis—Doxorubicin—liver cancer	0.000543	0.00109	CcSEcCtD
Sitaxentan—Jaundice—Doxorubicin—liver cancer	0.000543	0.00109	CcSEcCtD
Sitaxentan—Rhinitis—Epirubicin—liver cancer	0.000542	0.00109	CcSEcCtD
Sitaxentan—Conjunctivitis—Doxorubicin—liver cancer	0.000541	0.00109	CcSEcCtD
Sitaxentan—Haemorrhage—Epirubicin—liver cancer	0.00054	0.00109	CcSEcCtD
Sitaxentan—Hepatitis—Epirubicin—liver cancer	0.00054	0.00109	CcSEcCtD
Sitaxentan—Urinary tract disorder—Epirubicin—liver cancer	0.000534	0.00107	CcSEcCtD
Sitaxentan—Oedema peripheral—Epirubicin—liver cancer	0.000532	0.00107	CcSEcCtD
Sitaxentan—Haematuria—Doxorubicin—liver cancer	0.000531	0.00107	CcSEcCtD
Sitaxentan—Urethral disorder—Epirubicin—liver cancer	0.00053	0.00106	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Doxorubicin—liver cancer	0.000527	0.00106	CcSEcCtD
Sitaxentan—Epistaxis—Doxorubicin—liver cancer	0.000525	0.00106	CcSEcCtD
Sitaxentan—Sinusitis—Doxorubicin—liver cancer	0.000522	0.00105	CcSEcCtD
Sitaxentan—Visual impairment—Epirubicin—liver cancer	0.000521	0.00105	CcSEcCtD
Sitaxentan—Bradycardia—Doxorubicin—liver cancer	0.000509	0.00102	CcSEcCtD
Sitaxentan—Eye disorder—Epirubicin—liver cancer	0.000505	0.00101	CcSEcCtD
Sitaxentan—Tinnitus—Epirubicin—liver cancer	0.000504	0.00101	CcSEcCtD
Sitaxentan—Haemoglobin—Doxorubicin—liver cancer	0.000502	0.00101	CcSEcCtD
Sitaxentan—Cardiac disorder—Epirubicin—liver cancer	0.000501	0.00101	CcSEcCtD
Sitaxentan—Flushing—Epirubicin—liver cancer	0.000501	0.00101	CcSEcCtD
Sitaxentan—Rhinitis—Doxorubicin—liver cancer	0.000501	0.00101	CcSEcCtD
Sitaxentan—Hepatitis—Doxorubicin—liver cancer	0.0005	0.001	CcSEcCtD
Sitaxentan—Haemorrhage—Doxorubicin—liver cancer	0.0005	0.001	CcSEcCtD
Sitaxentan—Urinary tract disorder—Doxorubicin—liver cancer	0.000494	0.000992	CcSEcCtD
Sitaxentan—Oedema peripheral—Doxorubicin—liver cancer	0.000492	0.00099	CcSEcCtD
Sitaxentan—Angiopathy—Epirubicin—liver cancer	0.00049	0.000985	CcSEcCtD
Sitaxentan—Urethral disorder—Doxorubicin—liver cancer	0.00049	0.000985	CcSEcCtD
Sitaxentan—Immune system disorder—Epirubicin—liver cancer	0.000488	0.000981	CcSEcCtD
Sitaxentan—Mediastinal disorder—Epirubicin—liver cancer	0.000487	0.000979	CcSEcCtD
Sitaxentan—Visual impairment—Doxorubicin—liver cancer	0.000482	0.000968	CcSEcCtD
Sitaxentan—Alopecia—Epirubicin—liver cancer	0.000477	0.000959	CcSEcCtD
Sitaxentan—Mental disorder—Epirubicin—liver cancer	0.000473	0.000951	CcSEcCtD
Sitaxentan—Malnutrition—Epirubicin—liver cancer	0.00047	0.000945	CcSEcCtD
Sitaxentan—Eye disorder—Doxorubicin—liver cancer	0.000467	0.000939	CcSEcCtD
Sitaxentan—Tinnitus—Doxorubicin—liver cancer	0.000466	0.000937	CcSEcCtD
Sitaxentan—Flushing—Doxorubicin—liver cancer	0.000464	0.000932	CcSEcCtD
Sitaxentan—Cardiac disorder—Doxorubicin—liver cancer	0.000464	0.000932	CcSEcCtD
Sitaxentan—Tension—Epirubicin—liver cancer	0.000462	0.000927	CcSEcCtD
Sitaxentan—Nervousness—Epirubicin—liver cancer	0.000457	0.000918	CcSEcCtD
Sitaxentan—Angiopathy—Doxorubicin—liver cancer	0.000454	0.000911	CcSEcCtD
Sitaxentan—Muscle spasms—Epirubicin—liver cancer	0.000452	0.000909	CcSEcCtD
Sitaxentan—Immune system disorder—Doxorubicin—liver cancer	0.000452	0.000907	CcSEcCtD
Sitaxentan—Mediastinal disorder—Doxorubicin—liver cancer	0.000451	0.000905	CcSEcCtD
Sitaxentan—Alopecia—Doxorubicin—liver cancer	0.000442	0.000888	CcSEcCtD
Sitaxentan—Mental disorder—Doxorubicin—liver cancer	0.000438	0.00088	CcSEcCtD
Sitaxentan—Ill-defined disorder—Epirubicin—liver cancer	0.000436	0.000877	CcSEcCtD
Sitaxentan—Malnutrition—Doxorubicin—liver cancer	0.000435	0.000875	CcSEcCtD
Sitaxentan—Anaemia—Epirubicin—liver cancer	0.000435	0.000874	CcSEcCtD
Sitaxentan—Agitation—Epirubicin—liver cancer	0.000432	0.000869	CcSEcCtD
Sitaxentan—Tension—Doxorubicin—liver cancer	0.000427	0.000858	CcSEcCtD
Sitaxentan—Malaise—Epirubicin—liver cancer	0.000424	0.000852	CcSEcCtD
Sitaxentan—Nervousness—Doxorubicin—liver cancer	0.000423	0.000849	CcSEcCtD
Sitaxentan—Vertigo—Epirubicin—liver cancer	0.000423	0.000849	CcSEcCtD
Sitaxentan—Leukopenia—Epirubicin—liver cancer	0.000421	0.000846	CcSEcCtD
Sitaxentan—Muscle spasms—Doxorubicin—liver cancer	0.000418	0.000841	CcSEcCtD
Sitaxentan—Ill-defined disorder—Doxorubicin—liver cancer	0.000404	0.000811	CcSEcCtD
Sitaxentan—Anaemia—Doxorubicin—liver cancer	0.000402	0.000808	CcSEcCtD
Sitaxentan—Chest pain—Epirubicin—liver cancer	0.0004	0.000805	CcSEcCtD
Sitaxentan—Agitation—Doxorubicin—liver cancer	0.0004	0.000804	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000398	0.000799	CcSEcCtD
Sitaxentan—Discomfort—Epirubicin—liver cancer	0.000396	0.000795	CcSEcCtD
Sitaxentan—Malaise—Doxorubicin—liver cancer	0.000392	0.000789	CcSEcCtD
Sitaxentan—Dry mouth—Epirubicin—liver cancer	0.000392	0.000787	CcSEcCtD
Sitaxentan—Vertigo—Doxorubicin—liver cancer	0.000391	0.000786	CcSEcCtD
Sitaxentan—Leukopenia—Doxorubicin—liver cancer	0.00039	0.000783	CcSEcCtD
Sitaxentan—Confusional state—Epirubicin—liver cancer	0.000387	0.000778	CcSEcCtD
Sitaxentan—Oedema—Epirubicin—liver cancer	0.000384	0.000771	CcSEcCtD
Sitaxentan—Infection—Epirubicin—liver cancer	0.000381	0.000766	CcSEcCtD
Sitaxentan—Nervous system disorder—Epirubicin—liver cancer	0.000376	0.000756	CcSEcCtD
Sitaxentan—Thrombocytopenia—Epirubicin—liver cancer	0.000376	0.000755	CcSEcCtD
Sitaxentan—Tachycardia—Epirubicin—liver cancer	0.000375	0.000753	CcSEcCtD
Sitaxentan—Skin disorder—Epirubicin—liver cancer	0.000373	0.000749	CcSEcCtD
Sitaxentan—Chest pain—Doxorubicin—liver cancer	0.000371	0.000745	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000368	0.000739	CcSEcCtD
Sitaxentan—Discomfort—Doxorubicin—liver cancer	0.000366	0.000736	CcSEcCtD
Sitaxentan—Anorexia—Epirubicin—liver cancer	0.000366	0.000735	CcSEcCtD
Sitaxentan—Dry mouth—Doxorubicin—liver cancer	0.000362	0.000728	CcSEcCtD
Sitaxentan—Hypotension—Epirubicin—liver cancer	0.000359	0.000721	CcSEcCtD
Sitaxentan—Confusional state—Doxorubicin—liver cancer	0.000358	0.00072	CcSEcCtD
Sitaxentan—Oedema—Doxorubicin—liver cancer	0.000355	0.000714	CcSEcCtD
Sitaxentan—Infection—Doxorubicin—liver cancer	0.000353	0.000709	CcSEcCtD
Sitaxentan—Nervous system disorder—Doxorubicin—liver cancer	0.000348	0.0007	CcSEcCtD
Sitaxentan—Thrombocytopenia—Doxorubicin—liver cancer	0.000348	0.000699	CcSEcCtD
Sitaxentan—Insomnia—Epirubicin—liver cancer	0.000347	0.000698	CcSEcCtD
Sitaxentan—Tachycardia—Doxorubicin—liver cancer	0.000347	0.000697	CcSEcCtD
Sitaxentan—Skin disorder—Doxorubicin—liver cancer	0.000345	0.000693	CcSEcCtD
Sitaxentan—Somnolence—Epirubicin—liver cancer	0.000341	0.000686	CcSEcCtD
Sitaxentan—Anorexia—Doxorubicin—liver cancer	0.000339	0.00068	CcSEcCtD
Sitaxentan—Dyspepsia—Epirubicin—liver cancer	0.000338	0.000679	CcSEcCtD
Sitaxentan—Decreased appetite—Epirubicin—liver cancer	0.000334	0.000671	CcSEcCtD
Sitaxentan—Hypotension—Doxorubicin—liver cancer	0.000332	0.000667	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Epirubicin—liver cancer	0.000331	0.000666	CcSEcCtD
Sitaxentan—Fatigue—Epirubicin—liver cancer	0.000331	0.000665	CcSEcCtD
Sitaxentan—Pain—Epirubicin—liver cancer	0.000328	0.00066	CcSEcCtD
Sitaxentan—Constipation—Epirubicin—liver cancer	0.000328	0.00066	CcSEcCtD
Sitaxentan—Insomnia—Doxorubicin—liver cancer	0.000321	0.000646	CcSEcCtD
Sitaxentan—Feeling abnormal—Epirubicin—liver cancer	0.000316	0.000636	CcSEcCtD
Sitaxentan—Somnolence—Doxorubicin—liver cancer	0.000316	0.000635	CcSEcCtD
Sitaxentan—Dyspepsia—Doxorubicin—liver cancer	0.000313	0.000628	CcSEcCtD
Sitaxentan—Decreased appetite—Doxorubicin—liver cancer	0.000309	0.00062	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000307	0.000616	CcSEcCtD
Sitaxentan—Fatigue—Doxorubicin—liver cancer	0.000306	0.000615	CcSEcCtD
Sitaxentan—Urticaria—Epirubicin—liver cancer	0.000305	0.000613	CcSEcCtD
Sitaxentan—Constipation—Doxorubicin—liver cancer	0.000304	0.00061	CcSEcCtD
Sitaxentan—Pain—Doxorubicin—liver cancer	0.000304	0.00061	CcSEcCtD
Sitaxentan—Body temperature increased—Epirubicin—liver cancer	0.000303	0.00061	CcSEcCtD
Sitaxentan—Feeling abnormal—Doxorubicin—liver cancer	0.000293	0.000588	CcSEcCtD
Sitaxentan—Hypersensitivity—Epirubicin—liver cancer	0.000283	0.000568	CcSEcCtD
Sitaxentan—Urticaria—Doxorubicin—liver cancer	0.000282	0.000567	CcSEcCtD
Sitaxentan—Body temperature increased—Doxorubicin—liver cancer	0.000281	0.000564	CcSEcCtD
Sitaxentan—Asthenia—Epirubicin—liver cancer	0.000275	0.000553	CcSEcCtD
Sitaxentan—Diarrhoea—Epirubicin—liver cancer	0.000263	0.000528	CcSEcCtD
Sitaxentan—Hypersensitivity—Doxorubicin—liver cancer	0.000262	0.000526	CcSEcCtD
Sitaxentan—Asthenia—Doxorubicin—liver cancer	0.000255	0.000512	CcSEcCtD
Sitaxentan—Dizziness—Epirubicin—liver cancer	0.000254	0.00051	CcSEcCtD
Sitaxentan—Vomiting—Epirubicin—liver cancer	0.000244	0.00049	CcSEcCtD
Sitaxentan—Diarrhoea—Doxorubicin—liver cancer	0.000243	0.000488	CcSEcCtD
Sitaxentan—Rash—Epirubicin—liver cancer	0.000242	0.000486	CcSEcCtD
Sitaxentan—Dermatitis—Epirubicin—liver cancer	0.000242	0.000486	CcSEcCtD
Sitaxentan—Headache—Epirubicin—liver cancer	0.00024	0.000483	CcSEcCtD
Sitaxentan—Dizziness—Doxorubicin—liver cancer	0.000235	0.000472	CcSEcCtD
Sitaxentan—Nausea—Epirubicin—liver cancer	0.000228	0.000458	CcSEcCtD
Sitaxentan—Vomiting—Doxorubicin—liver cancer	0.000226	0.000454	CcSEcCtD
Sitaxentan—Rash—Doxorubicin—liver cancer	0.000224	0.00045	CcSEcCtD
Sitaxentan—Dermatitis—Doxorubicin—liver cancer	0.000224	0.00045	CcSEcCtD
Sitaxentan—Headache—Doxorubicin—liver cancer	0.000223	0.000447	CcSEcCtD
Sitaxentan—Nausea—Doxorubicin—liver cancer	0.000211	0.000424	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—HPGDS—liver cancer	0.000199	0.000669	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000197	0.000663	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—CYP1A1—liver cancer	0.000194	0.000651	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PRKCE—liver cancer	0.000193	0.00065	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PIK3CD—liver cancer	0.000191	0.000643	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP1A1—liver cancer	0.000191	0.000642	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.00019	0.000639	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ADAM17—liver cancer	0.00019	0.000639	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—GSTM1—liver cancer	0.000186	0.000626	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—GSTM1—liver cancer	0.000184	0.000618	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—PIK3CB—liver cancer	0.000184	0.000617	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IGF2—liver cancer	0.000183	0.000616	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.00018	0.000604	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—F2—liver cancer	0.000179	0.000602	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PSMA4—liver cancer	0.000179	0.000601	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PSMD10—liver cancer	0.000179	0.000601	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—CYP1A1—liver cancer	0.000177	0.000594	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP1A1—liver cancer	0.000174	0.000586	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000173	0.000583	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CG—liver cancer	0.000171	0.000576	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CSF2—liver cancer	0.000171	0.000575	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—RAF1—liver cancer	0.000171	0.000574	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—H2AFX—liver cancer	0.000169	0.000567	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—IL2—liver cancer	0.000169	0.000567	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PIK3CB—liver cancer	0.000167	0.00056	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—F2—liver cancer	0.000163	0.000547	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.000162	0.000545	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.00016	0.000538	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CG—liver cancer	0.000156	0.000523	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL2—liver cancer	0.000153	0.000515	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TERT—liver cancer	0.000153	0.000513	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CD—liver cancer	0.000151	0.000507	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GGT1—liver cancer	0.000149	0.0005	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000145	0.000489	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—UGDH—liver cancer	0.000145	0.000487	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KDR—liver cancer	0.000139	0.000469	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MAPK14—liver cancer	0.000139	0.000466	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PRKCE—liver cancer	0.000138	0.000465	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CD—liver cancer	0.000137	0.00046	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—EPT1—liver cancer	0.000136	0.000458	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ESR1—liver cancer	0.000136	0.000457	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—F2—liver cancer	0.000134	0.000451	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.000134	0.00045	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000133	0.000445	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—UGDH—liver cancer	0.000132	0.000444	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000132	0.000443	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CB—liver cancer	0.000131	0.000442	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IGF2—liver cancer	0.000131	0.000441	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TAT—liver cancer	0.000129	0.000434	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—APC—liver cancer	0.000129	0.000432	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CG—liver cancer	0.000129	0.000432	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000127	0.000427	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—EPT1—liver cancer	0.000124	0.000418	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GSTM1—liver cancer	0.000123	0.000413	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CSF2—liver cancer	0.000122	0.000412	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—RAF1—liver cancer	0.000122	0.000411	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	0.000121	0.000407	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—BRAF—liver cancer	0.000121	0.000406	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—H2AFX—liver cancer	0.000121	0.000406	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—IL2—liver cancer	0.000121	0.000406	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CB—liver cancer	0.000119	0.000401	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TAT—liver cancer	0.000118	0.000396	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.000117	0.000392	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000116	0.000389	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.000115	0.000386	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CD—liver cancer	0.000113	0.00038	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—PIK3CA—liver cancer	0.000112	0.000376	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SERPINE1—liver cancer	0.000112	0.000376	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—KRAS—liver cancer	0.000111	0.000372	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL2—liver cancer	0.00011	0.000368	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TERT—liver cancer	0.000109	0.000367	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PIK3CA—liver cancer	0.000102	0.000342	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—RAF1—liver cancer	0.000101	0.000339	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KDR—liver cancer	9.98e-05	0.000336	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAPK14—liver cancer	9.92e-05	0.000333	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CB—liver cancer	9.85e-05	0.000331	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MTOR—liver cancer	9.85e-05	0.000331	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ESR1—liver cancer	9.73e-05	0.000327	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—F2—liver cancer	9.61e-05	0.000323	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—GGT1—liver cancer	9.51e-05	0.00032	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—HRAS—liver cancer	9.4e-05	0.000316	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CDKN1B—liver cancer	9.24e-05	0.000311	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—APC—liver cancer	9.2e-05	0.000309	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CG—liver cancer	9.2e-05	0.000309	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—AKT1—liver cancer	9.14e-05	0.000307	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CASP3—liver cancer	9.06e-05	0.000304	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL2—liver cancer	9.04e-05	0.000304	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL6—liver cancer	9e-05	0.000302	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCND1—liver cancer	8.82e-05	0.000296	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—JUN—liver cancer	8.8e-05	0.000296	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GLUL—liver cancer	8.78e-05	0.000295	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CPT1B—liver cancer	8.78e-05	0.000295	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CTNNB1—liver cancer	8.73e-05	0.000293	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—UGDH—liver cancer	8.71e-05	0.000293	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	8.67e-05	0.000291	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—BRAF—liver cancer	8.64e-05	0.000291	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MMP9—liver cancer	8.56e-05	0.000288	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CDKN1A—liver cancer	8.53e-05	0.000287	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NR1H4—liver cancer	8.47e-05	0.000285	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MAPK8—liver cancer	8.32e-05	0.00028	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTA3—liver cancer	8.32e-05	0.00028	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—AKT1—liver cancer	8.3e-05	0.000279	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—EPT1—liver cancer	8.19e-05	0.000275	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CD—liver cancer	8.09e-05	0.000272	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CA—liver cancer	8.01e-05	0.000269	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GLUL—liver cancer	8e-05	0.000269	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CPT1B—liver cancer	8e-05	0.000269	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SERPINE1—liver cancer	8e-05	0.000269	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—KRAS—liver cancer	7.92e-05	0.000266	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TAT—liver cancer	7.77e-05	0.000261	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NR1H4—liver cancer	7.72e-05	0.000259	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—VEGFA—liver cancer	7.69e-05	0.000258	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTA4—liver cancer	7.61e-05	0.000256	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—STAT3—liver cancer	7.61e-05	0.000256	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTA3—liver cancer	7.59e-05	0.000255	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	7.44e-05	0.00025	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTA2—liver cancer	7.42e-05	0.000249	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CA—liver cancer	7.27e-05	0.000244	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RAF1—liver cancer	7.22e-05	0.000243	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTA1—liver cancer	7.16e-05	0.000241	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NAT2—liver cancer	7.08e-05	0.000238	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MYC—liver cancer	7.07e-05	0.000238	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TGFB1—liver cancer	7.05e-05	0.000237	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CB—liver cancer	7.05e-05	0.000237	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MTOR—liver cancer	7.05e-05	0.000237	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTA4—liver cancer	6.94e-05	0.000233	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—liver cancer	6.8e-05	0.000229	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ALDOB—liver cancer	6.78e-05	0.000228	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	6.78e-05	0.000228	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTA2—liver cancer	6.76e-05	0.000227	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—HRAS—liver cancer	6.73e-05	0.000226	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDKN1B—liver cancer	6.61e-05	0.000222	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AKT1—liver cancer	6.54e-05	0.00022	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KRAS—liver cancer	6.53e-05	0.00022	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTA1—liver cancer	6.53e-05	0.000219	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CASP3—liver cancer	6.48e-05	0.000218	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CRABP1—liver cancer	6.47e-05	0.000218	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL2—liver cancer	6.47e-05	0.000218	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NAT2—liver cancer	6.45e-05	0.000217	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL6—liver cancer	6.44e-05	0.000216	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCND1—liver cancer	6.31e-05	0.000212	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—JUN—liver cancer	6.3e-05	0.000212	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CTNNB1—liver cancer	6.25e-05	0.00021	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	6.2e-05	0.000209	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALDOB—liver cancer	6.19e-05	0.000208	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MMP9—liver cancer	6.13e-05	0.000206	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDKN1A—liver cancer	6.1e-05	0.000205	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CA—liver cancer	6e-05	0.000202	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAPK8—liver cancer	5.96e-05	0.0002	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AKT1—liver cancer	5.94e-05	0.0002	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CRABP1—liver cancer	5.9e-05	0.000198	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	5.83e-05	0.000196	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—liver cancer	5.81e-05	0.000195	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—HPGDS—liver cancer	5.66e-05	0.00019	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—liver cancer	5.62e-05	0.000189	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HRAS—liver cancer	5.55e-05	0.000187	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—VEGFA—liver cancer	5.5e-05	0.000185	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—STAT3—liver cancer	5.45e-05	0.000183	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL6—liver cancer	5.32e-05	0.000179	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	5.31e-05	0.000179	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CPT1B—liver cancer	5.28e-05	0.000177	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GLUL—liver cancer	5.28e-05	0.000177	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—HPGDS—liver cancer	5.16e-05	0.000173	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	5.13e-05	0.000172	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	5.12e-05	0.000172	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NR1H4—liver cancer	5.09e-05	0.000171	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MYC—liver cancer	5.06e-05	0.00017	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	5.06e-05	0.00017	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TGFB1—liver cancer	5.05e-05	0.00017	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PSMA4—liver cancer	5.04e-05	0.00017	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PSMD10—liver cancer	5.04e-05	0.00017	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTA3—liver cancer	5e-05	0.000168	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GOT2—liver cancer	4.91e-05	0.000165	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AKT1—liver cancer	4.9e-05	0.000165	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KRAS—liver cancer	4.68e-05	0.000157	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.67e-05	0.000157	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP2E1—liver cancer	4.61e-05	0.000155	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.61e-05	0.000155	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PSMA4—liver cancer	4.6e-05	0.000155	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PSMD10—liver cancer	4.6e-05	0.000155	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTA4—liver cancer	4.58e-05	0.000154	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GOT2—liver cancer	4.47e-05	0.00015	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.47e-05	0.00015	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTA2—liver cancer	4.46e-05	0.00015	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYCS—liver cancer	4.31e-05	0.000145	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTA1—liver cancer	4.3e-05	0.000145	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CA—liver cancer	4.3e-05	0.000144	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NAT2—liver cancer	4.26e-05	0.000143	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GGT1—liver cancer	4.23e-05	0.000142	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GOT1—liver cancer	4.23e-05	0.000142	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP2E1—liver cancer	4.21e-05	0.000141	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—liver cancer	4.16e-05	0.00014	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALDOB—liver cancer	4.08e-05	0.000137	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.07e-05	0.000137	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HRAS—liver cancer	3.97e-05	0.000134	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYCS—liver cancer	3.93e-05	0.000132	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CRABP1—liver cancer	3.89e-05	0.000131	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GGT1—liver cancer	3.86e-05	0.00013	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GOT1—liver cancer	3.86e-05	0.00013	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL6—liver cancer	3.8e-05	0.000128	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTP1—liver cancer	3.8e-05	0.000128	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—HMOX1—liver cancer	3.75e-05	0.000126	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AKT1—liver cancer	3.51e-05	0.000118	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTM1—liver cancer	3.5e-05	0.000117	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTP1—liver cancer	3.47e-05	0.000117	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—HMOX1—liver cancer	3.42e-05	0.000115	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HPGDS—liver cancer	3.4e-05	0.000114	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP1A1—liver cancer	3.31e-05	0.000111	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTM1—liver cancer	3.19e-05	0.000107	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—MTHFR—liver cancer	3.09e-05	0.000104	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PSMA4—liver cancer	3.03e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PSMD10—liver cancer	3.03e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PPARA—liver cancer	3.03e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP1A1—liver cancer	3.02e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GOT2—liver cancer	2.95e-05	9.92e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—MTHFR—liver cancer	2.82e-05	9.47e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP2E1—liver cancer	2.77e-05	9.32e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PPARA—liver cancer	2.76e-05	9.29e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.72e-05	9.15e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CG—liver cancer	2.6e-05	8.72e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYCS—liver cancer	2.59e-05	8.72e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GGT1—liver cancer	2.55e-05	8.56e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GOT1—liver cancer	2.55e-05	8.56e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PPARG—liver cancer	2.5e-05	8.42e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.48e-05	8.34e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CG—liver cancer	2.37e-05	7.95e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTP1—liver cancer	2.29e-05	7.69e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PPARG—liver cancer	2.28e-05	7.68e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CD—liver cancer	2.28e-05	7.67e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HMOX1—liver cancer	2.26e-05	7.58e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ALB—liver cancer	2.25e-05	7.57e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTM1—liver cancer	2.1e-05	7.07e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CD—liver cancer	2.08e-05	6.99e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALB—liver cancer	2.05e-05	6.9e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP1A1—liver cancer	1.99e-05	6.7e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CB—liver cancer	1.99e-05	6.68e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MTHFR—liver cancer	1.86e-05	6.24e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PPARA—liver cancer	1.82e-05	6.13e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CB—liver cancer	1.81e-05	6.1e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CG—liver cancer	1.56e-05	5.25e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PPARG—liver cancer	1.51e-05	5.06e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CD—liver cancer	1.37e-05	4.61e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALB—liver cancer	1.35e-05	4.55e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CA—liver cancer	1.21e-05	4.08e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CB—liver cancer	1.2e-05	4.02e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CA—liver cancer	1.11e-05	3.72e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AKT1—liver cancer	9.9e-06	3.33e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AKT1—liver cancer	9.03e-06	3.04e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CA—liver cancer	7.29e-06	2.45e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—AKT1—liver cancer	5.96e-06	2e-05	CbGpPWpGaD
